Keywords
Cardiomyopathy
Hypertension
Arrhythmia
Vascular damage
Submitted : 2021-08-31
Accepted : 2021-09-15
Published : 2021-09-30
Abstract
Acromegaly is a progressive disease caused by an increased in the levels of growth hormone (GH), followed by an increased in the levels of insulin-like growth factor-1 (IGF-1). Most cases are caused by GH-secreting pituitary adenomas. Long-term exposure to excessive GH would affect all systems of the body, of which the cardiovascular system has the highest incidence rate and mortality rate. This review discusses the influence of acromegaly on cardiovascular diseases and its treatment.
References
Sisco J, van der Lely AJ, 2021, Towards an Earlier Diagnosis of Acromegaly and Gigantism. Journal of Clinical Medicine, 10(7).
Melmed S, 2009, Acromegaly Pathogenesis and Treatment. The Journal of Clinical Investigation, 119(11): 3189-3202.
Colao A, Ferone D, Marzullo P, et al., 2004, Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocr Rev, 25: 102-152.
Colao A, Marzullo P, Di Somma C, et al., 2001, Growth Hormone and the Heart. Clin Endocrinol (Oxf), 54: 137-154.
Arcopinto M, Bobbio E, Bossone E, et al., 2013, The GH/IGF-1 Axis in Chronic Heart Failure. Endocr Metab Immune Disord Drug Targets, 13(1): 76-91.
Ramos-Leví AM, Marazuela M, 2019, Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them?. Frontiers in Endocrinology, 10: 120.
Mosca S, Paolillo S, Colao A, et al., 2013, Cardiovascular Involvement in Patients Affected by Acromegaly: An Appraisal. Int J Cardiol, 167(5): 1712-1718.
Matta MP, Caron P, 2003, Acromegalic Cardiomyopathy: A Review of the Literature. Pituitary, 6(4): 203-207.
Orme SM, McNally RJ, Cartwright RA, et al., 1998, Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83: 2730-2734.
Minniti G, Moroni C, Jaffrain-Rea ML, et al., 2001, Marked Improvement in Cardiovascular Function After Successful Transsphenoidal Surgery in Acromegalic Patients. Clin Endocrinol (Oxf), 55: 307-313.
Baldelli R, Ferretti E, Jaffrain-Rea ML, et al., 1999, Cardiac Effects of Slow-Release Lanreotide: A Slow-Release Somatostatin Analog in Acromegalic Patients. J Clin Endocrinol Metab, 84: 527-532.
Colao A, Marzullo P, Cuocolo A, et al., 2003, Reversal of Acromegalic Cardiomyopathy in Young but Not in Middle-Aged Patients After 12 Months of Treatment with the Depot Long-Acting Somatostatin Analogue Octreotide. Clin Endocrinol (Oxf), 58: 169-176.
Isgaard J, Arcopinto M, Karason K, et al., 2015, GH and the Cardiovascular System: An Update on a Topic at Heart. Endocrine, 48(1): 25-35.
González B, Vargas G, de Los Monteros ALE, et al., 2018, Persistence of Diabetes and Hypertension After Multimodal Treatment of Acromegaly. Clin Endocrinol Metab, 103(6): 2369-2375.
Mosca S, Paolillo S, Colao A, et al., 2013, Cardiovascular Involvement in Patients Affected by Acromegaly: An Appraisal. Int J Cardiol, 167(5): 1712-1718.
Deray G, Rieu M, Devynck MA, et al., 1987, Evidence of an Endogenous Digitalis-Like Factor in the Plasma of Patients with Acromegaly. N Engl J Med, 316(10): 575-580.
Attal P, Chanson P, 2010, Endocrine Aspects of Obstructive Sleep Apnea. Clin Endocrinol Metab, 95(2): 483-495.
Schutte AE, Volpe M, Tocci G, et al., 2014, Revisiting the Relationship between Blood Pressure and Insulin-Like Growth Factor-1. Hypertension, 63: 1070-1077.
Vitale G, Pivonello R, Auriemma RS, et al., 2005, Hypertension in Acromegaly and in the Normal Population: Prevalence and Determinants. Clin Endocrinol (Oxf), 63: 470-476.
Auriemma RS, Pivonello R, De Martino MC, et al., 2013, Treatment with GH Receptor Antagonist in Acromegaly: Effect on Cardiac Arrhythmias. Eur J Endocrinol, 168(1): 15-22.
Rodrigues EA, Caruana MP, Lahiri A, et al., 1989, Subclinical Cardiac Dysfunction in Acromegaly: Evidence for a Specific Disease of Heart Muscle. Br Heart J, 62: 185-194.
Bardy GH, Smith WM, Hood MA, et al., 2010, An Entirely Subcutaneous Implantable Cardioverter-Defibrillator. N Engl J Med, 363: 36-44.
Oflaz B, Pamukçu M, Meriç F, et al., 2010, Investigation of Early Atherosclerotic Changes in Acromegalic Patients. International Journal of Clinical Practice, 64(1): 39-44.
Paisley AN, Banerjee M, Rezai M, et al., 2011, Changes in Arterial Stiffness but Not Carotid Intimal Thickness in Acromegaly. The Journal of Clinical Endocrinology & Metabolism, 96(5): 1486-1492.
Anagnostis P, Efstathiadou Z, Gougoura S, et al., 2013, Oxidative Stress and Reduced Antioxidative Status, along with Endothelial Dysfunction in Acromegaly. Horm Metab Res, 45(4): 314-318.
Hong F, Liang X, Liu W, et al., 2019, Roles of eNOS in Atherosclerosis Treatment[J]. Inflammation Research, 68(6): 429-441.
Boero L, Cuniberti L, Magnani N, et al., 2010, Increased Oxidized Low Density Lipoprotein Associated with High Ceruloplasmin Activity in Patients with Active Acromegaly. Clinical Endocrinology, 72(5): 654-660.
Ronconi V, Giacchetti G, Mariniello B, et al., 2005, Reduced Nitric Oxide Levels in Acromegaly: Cardiovascular Implications. Blood Pressure, 14(4): 227-232.